US Pharmaceutical Company Sees Nanotechnology As Key For Innovative Skincare Line
NWN Hears from DermAvance CEO Keith Greathouse to Learn More About The Companyâs Connection Between Nano and Advanced Skin Care.DermAvance Pharmaceuticals, a privately-held pharmaceutical company in Pennsylvania, recently announced that it has acquired the North American rights for the Hyalogyâ¢ Total Skin Care Line from Forlleâd in Japan. âHyalogy is the first topical hyaluronic acid of its kind in the US,â said DermAvance CEO Keith Greathouse. He explains to NWN that Hyalogy âis based on patented novel nanotechnology which reduces the size of the hyaluronic acid molecule, allowing it to penetrate deep beneath the epidermal barrier without losing its moisture retention ability. Hyalogy (topical Hyaluronic acid) has the power to penetrate deep beneath the epidermal barrier delivering moisture to the skin.â
By incorporating Hyalogy into its cosmeceutical product line, DermAvance believes it will have created a skin care line that provides a more effective and longer lasting method by which to deeply hydrate the skin. The Hyalogy line of products will be rolled out in the fall of 2006, and âwill be sold for use in offices to aesthetic physicians, dermatologists, and plastic surgeons,â notes Mr. Greathouse.